Human Herpesvirus Type 8 (HHV Type 8), also known as Kaposi’s Sarcoma-Associated Herpesvirus (KSHV), is a member of the herpesvirus family that has been linked to various malignancies and immune-related disorders. Understanding HHV-8 is essential for medical professionals, especially those in oncology, infectious diseases, and immunology. This article provides a comprehensive overview of HHV-8, including its types, function, related studies, treatment considerations, and clinical significance.
Snapshot
- A 45-year-old man with a history of HIV infection presents to his primary care doctor for a rash. He had been on antiretroviral medications for his HIV infection for years. Six months ago, he lost his job and his insurance and ran out of medication 5 months ago. He had been feeling fine until a week ago when he developed a painless rash on his face, trunk, and legs. He has also had some night sweats and low-grade fevers. On physical exam, he has multiple scattered reddish purple macules and papules. There are also purple nodules on his oral mucosa. A skin biopsy reveals neoplastic spindle-shaped cells and a lymphocytic infiltrate.
Introduction – HHV Type 8
- Classification
- Epidemiology
- demographics
- endemic in Africa
- causes soft tissue tumors
- adults > children
- endemic in Africa
- location
- skin, lungs, lymph nodes, and gastrointestinal tract
- risk factors
- HIV/AIDS
- acquired through sexual contact
- rarely seen in AIDS acquired through injection drug use
- post-transplant
- HIV/AIDS
- demographics
- Pathogenesis
- HHV-8 inhibits tumor suppression pathways
- Associated conditions
- diabetes mellitus
- autoimmune hemolytic anemia
- Prevention
- highly active antiretroviral therapy (HAART)
- annual skin exam in those at risk
- Prognosis
- progression is slow
- recurrence is likely
Presentation
- Symptoms
- B symptoms (fevers, night sweats, and weight loss)
- painless skin lesions
- may have pain associated with internal lesions
- Physical exam
- lymph nodes may be enlarged
Types of HHV-8 Infections:
- Primary Infection: HHV-8 primarily infects immune cells, particularly B cells and endothelial cells. Primary infection can be asymptomatic or cause mild flu-like symptoms.
- Latent Infection: After primary infection, HHV-8 establishes latent infection in host cells. During latency, the virus remains dormant and does not cause symptoms.
- Reactivation: HHV-8 can reactivate under certain conditions, such as immunosuppression or inflammation, leading to viral replication and the potential for disease development.
Function of HHV-8:
HHV-8 has been associated with various malignancies and conditions, including:
- Kaposi’s Sarcoma (KS): HHV-8 is strongly linked to KS, a cancer that primarily affects the skin, mucous membranes, and internal organs. KS lesions often appear as purplish or reddish patches or nodules.
- Primary Effusion Lymphoma (PEL): PEL is a type of non-Hodgkin lymphoma associated with HHV-8. It typically involves body cavities and is often seen in individuals with compromised immune systems.
- Multicentric Castleman Disease (MCD): MCD is a rare disorder characterized by enlarged lymph nodes and flu-like symptoms. HHV-8 has been implicated in some cases of MCD.
Studies
- Labs
- evaluate CD4+ count if AIDS is suspected
- Skin biopsy
- neoplastic spindle-shaped cells that form clefts and vascular channels
- lymphocytic infiltrate
- Making the diagnosis
- based on clinical presentation and confirmed with skin biopsy
- Epidemiological Studies: Epidemiological studies help to understand the prevalence of HHV-8 infections in different populations and its association with various diseases.
- Laboratory Studies: Laboratory studies investigate the molecular and cellular mechanisms of HHV-8 infection, replication, latency, and reactivation.
Clinical Significance:
- KS Diagnosis and Treatment: HHV-8 is a key factor in the development of KS. Diagnosis involves clinical examination, biopsy, and laboratory tests. Treatment depends on the type and extent of KS and may include surgery, radiation therapy, chemotherapy, or targeted therapies.
- PEL Management: PEL is an aggressive lymphoma often occurring in immunocompromised individuals. Treatment may include chemotherapy and antiviral therapies targeting HHV-8.
Differential
- Bacillary angiomatosis
- distinguishing factors
- rash manifests as dark red and purple papules, nodules, and plaques
- distinguishing factors
- skin biopsy reveals neutrophilic infiltrate
Treatment
- Management approach
- HAART in those with AIDS-related disease is mainstay of treatment
- patients should discontinue any immunosuppressants
- Medical
- vincristine
- indication
- AIDS-related disease
- indication
- interferon
- indication
- AIDS-related disease
- indication
- chemotherapy and radiation therapy
- indication
- vincristine
- widespread or rapidly progressing disease
Complications
- Metastatic progression of the disease
Conclusion:
HHV 8, or Kaposi’s Sarcoma-Associated Herpesvirus, is a member of the herpesvirus family that is linked to several malignancies and immune-related disorders. It primarily infects B cells and endothelial cells, establishing a latent infection that can reactivate under certain conditions. HHV 8 is strongly associated with Kaposi’s sarcoma (KS), primary effusion lymphoma (PEL), and multicentric Castleman disease (MCD). KS lesions are characteristic purplish or reddish patches or nodules.
PEL is an aggressive lymphoma that often occurs in immunocompromised individuals. HHV 8-related diseases can be diagnosed through clinical examination, biopsies, and laboratory tests. Treatment strategies depend on the specific condition, ranging from antiretroviral therapy and antiviral treatments to chemotherapy and targeted therapies.
Check out USMLE Step 1 Mastery: Comprehensive Course and Lecture Notes